Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus

Journal of Immunology

Volumn 188, Issue 8, 2012, Pages 4113-4121

  Xu, Yuan ^a   Lee, Pui Y ^a,c   Li, Yi ^a   Liu, Chao ^b   Zhuang, Haoyang ^a   Han, Shuhong ^a   Nacionales, Dina C ^b   Weinstein, Jason ^a,d   Mathews, Clayton E ^b   Moldawer, Lyle L ^b   Li, Shi Wu ^b   Satoh, Minoru ^a,b   Yang, Li Jun ^b   Reeves, Westley H ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 4; LYSINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MYELOID DIFFERENTIATION FACTOR 88; PRISTANE; RIBONUCLEOPROTEIN ANTIBODY; SECONDARY LYMPHOID TISSUE CHEMOKINE; SM ANTIBODY; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL MODEL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; WILD TYPE;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CARCINOGENS; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON REGULATORY FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; T-LYMPHOCYTE SUBSETS; TERPENES; TH1-TH2 BALANCE;

EID: 84860351105     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103113     Document Type: Article

References (38)

1. Takaoka, A., H. Yanai, S. Kondo, G. Duncan, H. Negishi, T. Mizutani, S. Kano, K. Honda, Y. Ohba, T. W. Mak, and T. Taniguchi. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249. (Pubitemid 40388058)
2. Barnes, B. J., P. A. Moore, and P. M. Pitha. 2001. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276: 23382-23390.
3. Schoenemeyer, A., B. J. Barnes, M. E. Mancl, E. Latz, N. Goutagny, P. M. Pitha, K. A. Fitzgerald, and D. T. Golenbock. 2005. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 280: 17005-17012. (Pubitemid 41389162)
4. Couzinet, A., K. Tamura, H. M. Chen, K. Nishimura, Z. Wang, Y. Morishita, K. Takeda, H. Yagita, H. Yanai, T. Taniguchi, and T. Tamura. 2008. A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc. Natl. Acad. Sci. USA 105: 2556-2561. (Pubitemid 351520552)
5. Lien, C., C. M. Fang, D. Huso, F. Livak, R. Lu, and P. M. Pitha. 2010. Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl. Acad. Sci. USA 107: 4664-4668.
6. Savitsky, D. A., H. Yanai, T. Tamura, T. Taniguchi, and K. Honda. 2010. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc. Natl. Acad. Sci. USA 107: 10154-10159.
7. Graham, R. R., C. Kyogoku, S. Sigurdsson, I. A. Vlasova, L. R. Davies, E. C. Baechler, R. M. Plenge, T. Koeuth, W. A. Ortmann, G. Hom, et al. 2007. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. USA 104: 6758-6763. (Pubitemid 47175574)
8. Mancl, M. E., G. Hu, N. Sangster-Guity, S. L. Olshalsky, K. Hoops, P. Fitzgerald-Bocarsly, P. M. Pitha, K. Pinder, and B. J. Barnes. 2005. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J. Biol. Chem. 280: 21078-21090. (Pubitemid 40805667)
9. Feng, D., R. C. Stone, M. L. Eloranta, N. Sangster-Guity, G. Nordmark, S. Sigurdsson, C. Wang, G. Alm, A. C. Syvanen, L. Ronnblom, and B. J. Barnes. 2010. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 62: 562-573.
10. Niewold, T. B., J. A. Kelly, M. H. Flesch, L. R. Espinoza, J. B. Harley, and M. K. Crow. 2008. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58: 2481-2487.
11. Paun, A., J. T. Reinert, Z. Jiang, C. Medin, M. Y. Balkhi, K. A. Fitzgerald, and P. M. Pitha. 2008. Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J. Biol. Chem. 283: 14295-14308.
12. Graham, R. R., S. V. Kozyrev, E. C. Baechler, M. V. Reddy, R. M. Plenge, J. W. Bauer, W. A. Ortmann, T. Koeuth, M. F. Gonzalez Escribano, B. Pons-Estel, et al. 2006. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38: 550-555.
13. Sigurdsson, S., G. Nordmark, H. H. Goring, K. Lindroos, A. C. Wiman, G. Sturfelt, A. Jonsen, S. Rantapaa-Dahlqvist, B. Moller, J. Kere, et al. 2005. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76: 528-537. (Pubitemid 40250533)
14. Harley, I. T., K. M. Kaufman, C. D. Langefeld, J. B. Harley, and J. A. Kelly. 2009. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 10: 285-290.
15. Rullo, O. J., J. M. Woo, H. Wu, A. D. Hoftman, P. Maranian, B. A. Brahn, D. McCurdy, R. M. Cantor, and B. P. Tsao. 2010. Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann. Rheum. Dis. 69: 611-617.
16. -/- mouse models of systemic lupus erythematosus. J. Immunol. 184: 796-806.
17. Tada, Y., S. Kondo, S. Aoki, S. Koarada, H. Inoue, R. Suematsu, A. Ohta, T. W. Mak, and K. Nagasawa. 2011. Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. Arthritis Rheum. 63: 738-748.
18. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173: 2134-2142. (Pubitemid 38971652)
19. Reeves, W. H., P. Y. Lee, J. S. Weinstein, M. Satoh, and L. Lu. 2009. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 30: 455-464.
20. Lee, P. Y., Y. Kumagai, Y. Li, O. Takeuchi, H. Yoshida, J. Weinstein, E. S. Kellner, D. Nacionales, T. Barker, K. Kelly-Scumpia, et al. 2008. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205: 2995-3006.
21. Lee, P. Y., Y. Li, Y. Kumagai, Y. Xu, J. S. Weinstein, E. S. Kellner, D. C. Nacionales, E. J. Butfiloski, N. van Rooijen, S. Akira, et al. 2009. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am. J. Pathol. 175: 2023-2033.
22. Richards, H. B., M. Satoh, M. Shaw, C. Libert, V. Poli, and W. H. Reeves. 1998. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188: 985-990. (Pubitemid 28433425)
23. Nacionales, D. C., J. S. Weinstein, X. J. Yan, E. Albesiano, P. Y. Lee, K. M. Kelly-Scumpia, R. Lyons, M. Satoh, N. Chiorazzi, and W. H. Reeves. 2009. B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. J. Immunol. 182: 4226-4236.
24. Nacionales, D. C., K. M. Kelly-Scumpia, P. Y. Lee, J. S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W. H. Reeves. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56: 3770-3783. (Pubitemid 350100710)
25. Sobel, E. S., V. N. Kakkanaiah, M. Kakkanaiah, R. L. Cheek, P. L. Cohen, and R. A. Eisenberg. 1994. T-B collaboration for autoantibody production in lpr mice is cognate and MHC-restricted. J. Immunol. 152: 6011-6016. (Pubitemid 24174184)
26. Satoh, M., H. B. Richards, V. M. Shaheen, H. Yoshida, M. Shaw, J. O. Naim, P. H. Wooley, and W. H. Reeves. 2000. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin. Exp. Immunol. 121: 399-405. (Pubitemid 30659782)
27. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5: 521-531. (Pubitemid 40961330)
28. Lee, P. Y., Y. Kumagai, Y. Xu, Y. Li, T. Barker, C. Liu, E. S. Sobel, O. Takeuchi, S. Akira, M. Satoh, and W. H. Reeves. 2011. IL-1alpha modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. J. Immunol. 186: 1747-1754.
29. Lee, P. Y., J. S. Weinstein, D. C. Nacionales, P. O. Scumpia, Y. Li, E. Butfiloski, N. van Rooijen, L. Moldawer, M. Satoh, and W. H. Reeves. 2008. A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180: 5101-5108.
30. Paun, A., R. Bankoti, T. Joshi, P. M. Pitha, and S. Stager. 2011. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection. PLoS Pathog. 7: e1001246.
31. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2: 845-858. (Pubitemid 37328707)
32. Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. Feldmann, and I. A. Udalova. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12: 231-238.
33. Shiow, L. R., D. B. Rosen, N. Brdickova, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-alpha/ beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
34. Seth, S., L. Oberdorfer, R. Hyde, K. Hoff, V. Thies, T. Worbs, S. Schmitz, and R. Forster. 2011. CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions. J. Immunol. 186: 3364-3372.
35. Niewold, T. B., J. A. Kelly, S. N. Kariuki, B. S. Franek, A. A. Kumar, K. M. Kaufman, K. Thomas, D. Walker, S. Kamp, J. M. Frost, et al. 2011. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 71: 463-469.
36. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6: 644-658. (Pubitemid 44298214)
37. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189: 521-530.
38. Richards, H. B., M. Satoh, J. C. Jennette, B. P. Croker, H. Yoshida, and W. H. Reeves. 2001. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 60: 2173-2180. (Pubitemid 33070460)